Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NC410 |
Synonyms | |
Therapy Description |
NC410 is a dimeric Lair2 fusion protein that binds collagen and inhibits its interaction with Lair1, resulting in decreased Lair1 downstream signaling and potentially leading to enhanced antitumor immune response and inhibition of tumor growth (PMID: 34121658). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NC410 | NC-410|NC 410 | NC410 is a dimeric Lair2 fusion protein that binds collagen and inhibits its interaction with Lair1, resulting in decreased Lair1 downstream signaling and potentially leading to enhanced antitumor immune response and inhibition of tumor growth (PMID: 34121658). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04408599 | Phase Ib/II | NC410 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |